LQDA · Liquidia Corporation · Stock research

Current Thesis

The coiled legal binary that defined this name at $55 in early June has largely paid out, and the tape is now a momentum grind at new highs rather than a pre-discovery asymmetry. Three catalysts stacked and cleared: the 2026-06-04 SCOTUS Hikma v. Amarin ruling raised the induced-infringement bar for skinny labels (read by HC Wainwright as tilting the '327 dispute toward damages over a forced YUTREPIA withdrawal); S&P SmallCap 600 inclusion went effective 2026-06-22; and BTIG doubled its target to $109 from $59 on 2026-06-22. Price ran +45% off the June base to a fresh 52-week high of $82.96, closing $79.94 on 2026-07-17 (+6.2%) after a +7.4% day on 2026-07-14. The commercial engine is real Q1'26 YUTREPIA net sales $129.9M, +44% QoQ, third straight profitable quarter but the setup has inverted: price now trades above the ~$68.88 consensus target, two fresh Sell ratings have appeared, BofA cut to Neutral on valuation, and Judge Andrews' '327 bench ruling is still outstanding and can land any day. Narrative is MATURING; a buy at $80 chases strength into an Aug 6 print, not a discounted binary.

Bullish and bearish views on Liquidia Corporation

The model's bull view on Liquidia Corporation (LQDA), in brief: Ramp still compounding Q1'26 (call 2026-05-11): YUTREPIA net sales $129.9M, +44% sequential off Q4'25's ~$90M; total revenue $132.9M beat $116.7M consensus; EPS $0.52 vs $0.41; net income $52.9M; adj EBITDA $71.2M; cash ~$223M, self-funded. The bear view: Above consensus into a pending ruling at $79.94 the stock sits ~16% above the ~$68.88 consensus 12-month target; only BTIG's $109 is higher, and the target range runs down to $28. Both cases follow in full.

Bull Case

• Ramp still compounding Q1'26 (call 2026-05-11): YUTREPIA net sales $129.9M, +44% sequential off Q4'25's ~$90M; total revenue $132.9M beat $116.7M consensus; EPS $0.52 vs $0.41; net income $52.9M; adj EBITDA $71.2M; cash ~$223M, self-funded.
• Peak-sales bar reset higher Street peak YUTREPIA estimates now cited at $1.7–2.0B vs management's still-reiterated "~$1B net revenue by 2027"; 2026 consensus revenue is ~$717M (+149% YoY) with consensus EPS ~$3.26. The estimate path is widening, not topping.
• Legal tail structurally cut the 2026-06-04 SCOTUS skinny-label decision makes a forced YUTREPIA withdrawal far harder to win; the feared 2026-06-23 trial date elapsed with no injunction; full FDA approval (2025-05-23, both PAH and PH-ILD) is unaffected by any '327 outcome. LQDA's counter-suit on the '494 dosing-regimen patent adds settlement leverage.
• Mechanical + Street sponsorship S&P SmallCap 600 inclusion (eff 2026-06-22) forced index buying; BTIG's $109 (2026-06-22) is the Street high, and even BofA's downgrade lifted its number to $79 (2026-06-29). Ratings remain Moderate Buy (3 Strong Buy / 5 Buy).
• '327 is narrow the patent covers PH-ILD only, not the larger PAH market where YUTREPIA also carries approval.

Bear Case

• Above consensus into a pending ruling at $79.94 the stock sits ~16% above the ~$68.88 consensus 12-month target; only BTIG's $109 is higher, and the target range runs down to $28. Judge Andrews' '327 merits decision remains un-issued; a damages-vs-injunction surprise hits the single revenue engine with no warning.
• Analysts turning on valuation BofA (Gerberry) cut Buy→Neutral on 2026-06-29 even while raising its PT to $79, an explicit "fairly valued" call; the board now shows 2 Sell ratings and 1 Hold against the buys. The easy repricing (~7x off the 52-wk low) is done.
• Insider distribution into the highs CEO Roger Jeffs sold 75k shares (2026-05-08) and 75k (2026-05-21); Director Raman Singh 29,494 (2026-05-21); Management is a net seller into new-high prints.
• Single-product concentration YUTREPIA is ~98% of revenue; any commercial slip or adverse legal turn hits the whole thesis at once. L606 (sustained-release treprostinil, Phase 3) is early and not a 2026 contributor.
• Premium on trailing math ~$7.0B market cap on a trailing P/E north of 300; the multiple only compresses if the $1.7–2B peak path actually arrives. Entrenched, cash-rich UTHR (Tyvaso DPI) defends the franchise aggressively.

Setup & Price Structure

Momentum is intact but extended. The June leg launched off a higher-low base (~$62) after the 2026-06-04 SCOTUS pop to $65.77, broke out on S&P inclusion, and has since built a shelf in the $76–80 zone through July $77.93 (07-10), $76.49 (07-14, +7.4%), $79.94 (07-17, +6.2%) printing a fresh 52-week high at $82.96. Price is stretched well above rising moving averages and above every analyst target except one. This is a name that has already made its asymmetric move; a fresh long at the high buys distribution risk (insiders + 2 Sell ratings) with a binary bench ruling hanging over it. The disciplined read on a MATURING momentum name is to stand aside and wait for a pullback to the breakout shelf rather than chase the vertical the June-style entry at a defined higher-low, not the parabolic extension.

Catalyst Calendar (next 30 days)

• ~any day, unscheduled Judge Andrews' '327 bench ruling (D. Del., 1:23-cv-00975, PH-ILD only). No fixed date; the single largest swing factor. Damages ≈ bullish continuation; a permanent PH-ILD injunction ≈ sharp gap risk.
• 2026-08-06 (est., confirmed by earnings trackers) Q2'26 earnings. Watch YUTREPIA net-sales sequential vs Q1's $129.9M, gross-to-net, and any peak-guidance revision.
• Ongoing S&P SmallCap 600 index flows have largely cleared post-06-22; residual rebalancing demand is fading as a driver.

What Would Change Our Mind

The momentum thesis breaks on a weekly close below $70, which loses the July breakout shelf built above the S&P-inclusion base and drops price back under the ~$68.88 consensus target the signal that distribution has won and the leg has rolled over (next shelf ~$62, then the $54–57 base). Independent of price, the read flips if Judge Andrews' '327 ruling grants UTHR a permanent PH-ILD injunction rather than damages, or if the 2026-08-06 Q2 print shows YUTREPIA net sales failing to grow off Q1's $129.9M (sequential ramp stalling). Conversely, a favorable '327 damages ruling plus a clean Q2 beat would re-rate the peak-sales case and justify chasing on a controlled pullback rather than at the high.

Correlation Notes

LQDA is structurally inverse to UTHR the '327 outcome and YUTREPIA's share gains come directly at the Tyvaso franchise's expense so holding both long as a "PAH theme basket" cancels the edge. Broader inhaled-prostacyclin/PAH read-throughs (INSM, and Tyvaso-adjacent names) share the legal-precedent tape. As a newly-added S&P SmallCap 600 constituent the name now carries small-cap index beta it lacked before 06-22. Sensitivity to biotech-factor risk-off is high given the ~300x trailing multiple and single-product concentration; a broad small-cap or biotech drawdown would pressure this harder than the diversified group.